Should I buy or sell Kiniksa Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" KNSA shares. View KNSA analyst ratings or view top-rated stocks .

What is Kiniksa Pharmaceuticals' stock price target for 2024?

1 Wall Street research analysts have issued 12-month price targets for Kiniksa Pharmaceuticals' shares. Their KNSA share price targets range from $30.00 to $30.00. On average, they predict the company's share price to reach $30.00 in the next twelve months. This suggests a possible upside of 77.4% from the stock's current price. View analysts price targets for KNSA or view top-rated stocks among Wall Street analysts .

How have KNSA shares performed in 2024?

Kiniksa Pharmaceuticals' stock was trading at $17.54 at the beginning of the year. Since then, KNSA shares have decreased by 3.6% and is now trading at $16.91. View the best growth stocks for 2024 here .

Are investors shorting Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,210,000 shares, an increase of 11.8% from the March 15th total of 2,870,000 shares. Based on an average trading volume of 375,600 shares, the short-interest ratio is currently 8.5 days. View Kiniksa Pharmaceuticals' Short Interest .

When is Kiniksa Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 23rd 2024. View our KNSA earnings forecast .

How can I listen to Kiniksa Pharmaceuticals' earnings call?

Kiniksa Pharmaceuticals will be holding an earnings conference call on Tuesday, April 23rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link .

How were Kiniksa Pharmaceuticals' earnings last quarter?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) released its quarterly earnings results on Wednesday, February, 28th. The company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.15. The company had revenue of $83.40 million for the quarter, compared to analyst estimates of $72.31 million. Kiniksa Pharmaceuticals had a net margin of 5.11% and a negative trailing twelve-month return on equity of 6.12%.

What ETF holds Kiniksa Pharmaceuticals' stock?

Virtus LifeSci Biotech Products ETF holds 22,347 shares of KNSA stock, representing 2.12% of its portfolio.

What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO?

1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com . Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Kiniksa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL) , CRISPR Therapeutics (CRSP) , Pfizer (PFE) , VBI Vaccines (VBIV) , SCYNEXIS (SCYX) , Sorrento Therapeutics (SRNE) , AbbVie (ABBV) , Dicerna Pharmaceuticals (DRNA) , Vaxart (VXRT) and Advanced Micro Devices (AMD) .

When did Kiniksa Pharmaceuticals IPO?

Kiniksa Pharmaceuticals (KNSA) raised $126 million in an IPO on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Kiniksa Pharmaceuticals' major shareholders?

Kiniksa Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.20%), Hennion & Walsh Asset Management Inc. (0.18%) and Allspring Global Investments Holdings LLC (0.09%). Insiders that own company stock include Barry D Quart, John F Paolini, Mark Ragosa, Michael R Megna and Sanj K Patel. View institutional ownership trends .

How do I buy shares of Kiniksa Pharmaceuticals?

Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:KNSA

Kiniksa Pharmaceuticals (KNSA) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free KNSA Stock Alerts

$16.91

+0.03 (+0.18%)

(As of 05:21 PM ET)

Compare

Today's Range: $16.56
▼
$17.15
50-Day Range: $16.88
▼
$21.74
52-Week Range: $10.65
▼
$22.09

Volume: 375,954 shs
Average Volume: 400,534 shs
Market Capitalization: $1.19 billion

P/E Ratio: 93.95
Dividend Yield: N/A
Price Target: $30.00

Get Kiniksa Pharmaceuticals alerts:

Kiniksa Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 77.4% Upside
$30.00 Price Target
Short Interest: Bearish
4.55% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.65
Based on 3 Articles This Week
Insider Trading: Selling Shares
$709,929 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.06) to ($0.44) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.11 out of 5 stars

Medical Sector

378th out of 918 stocks

Pharmaceutical Preparations Industry

165th out of 416 stocks

3.5

Analyst's Opinion

Consensus Rating
Kiniksa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Kiniksa Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.55% of the outstanding shares of Kiniksa Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Kiniksa Pharmaceuticals has a short interest ratio ("days to cover") of 8.5.
Change versus previous month
Short interest in Kiniksa Pharmaceuticals has recently increased by 11.85%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Kiniksa Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Kiniksa Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for KNSA.

3.1

News and Social Media Coverage

News Sentiment
Kiniksa Pharmaceuticals has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Kiniksa Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
3 people have searched for KNSA on MarketBeat in the last 30 days.
MarketBeat Follows
Only 2 people have added Kiniksa Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kiniksa Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $709,929.00 in company stock.
Percentage Held by Insiders
54.23% of the stock of Kiniksa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
53.95% of the stock of Kiniksa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Kiniksa Pharmaceuticals are expected to decrease in the coming year, from ($0.06) to ($0.44) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kiniksa Pharmaceuticals is 93.95, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.45.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kiniksa Pharmaceuticals is 93.95, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 215.55.
Price to Book Value per Share Ratio
Kiniksa Pharmaceuticals has a P/B Ratio of 2.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Kiniksa Pharmaceuticals Stock (NASDAQ:KNSA)

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

KNSA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KNSA Stock News Headlines

April 16, 2024 | globenewswire.com

Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024

April 16, 2024 | americanbankingnews.com

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Short Interest Up 11.8% in March

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

April 2, 2024 | globenewswire.com

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart

March 7, 2024 | msn.com

5 Biotech Stocks With 26% Upside Potential or More

March 3, 2024 | investing.com

Earnings call: Kiniksa Pharmaceuticals sees robust growth in ARCALYST sales

March 3, 2024 | wsj.com

Kiniksa Pharmaceuticals Ltd.

March 1, 2024 | seekingalpha.com

Kiniksa Pharmaceuticals Ltd. (KNSA) Q4 2023 Earnings Call Transcript

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 1, 2024 | finance.yahoo.com

Kiniksa Pharmaceuticals Full Year 2023 Earnings: Beats Expectations

March 1, 2024 | finance.yahoo.com

Chief Medical Officer John Paolini Sells 10,156 Shares of Kiniksa Pharmaceuticals Ltd (KNSA)

February 29, 2024 | finance.yahoo.com

Are You Looking for a Top Momentum Pick? Why Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Great Choice

February 29, 2024 | finance.yahoo.com

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2023 Earnings Call Transcript

February 28, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: G1 Therapeutics (GTHX), Kiniksa Pharmaceuticals (KNSA)

February 28, 2024 | finance.yahoo.com

Kiniksa Pharmaceuticals Ltd (KNSA) Reports Strong Revenue Growth in Q4 and Full-Year 2023

February 28, 2024 | globenewswire.com

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution

February 28, 2024 | markets.businessinsider.com

What Wall Street expects from Kiniksa Pharmaceuticals's earnings

February 21, 2024 | finance.yahoo.com

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

February 21, 2024 | globenewswire.com

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

February 12, 2024 | msn.com

Wall Street Analysts Predict a 38.07% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Here's What You Should Know

February 12, 2024 | finance.yahoo.com

Kiniksa Pharmaceuticals, Ltd. (KNSA) is on the Move, Here's Why the Trend Could be Sustainable

February 12, 2024 | finance.yahoo.com

Wall Street Analysts Predict a 38.07% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Here's What You Should Know

January 31, 2024 | uk.finance.yahoo.com

GSK (GSK) Misses Q4 Earnings Estimates

January 23, 2024 | finance.yahoo.com

How Much Upside is Left in Kiniksa Pharmaceuticals, Ltd. (KNSA)? Wall Street Analysts Think 43.93%

January 15, 2024 | finance.yahoo.com

Investors in Kiniksa Pharmaceuticals (NASDAQ:KNSA) have seen returns of 30% over the past year

January 9, 2024 | msn.com

Is Kiniksa Pharmaceuticals (KNSA) Stock a Solid Choice Right Now?

January 5, 2024 | seekingalpha.com

Kiniksa Pharmaceuticals: Early 2024 Corporate Update A Mixed Bag

See More Headlines

Receive KNSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/19/2024
Next Earnings (Confirmed): 4/23/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:KNSA
CUSIP: N/A
CIK: 1730430
Web: www.kiniksa.com
Phone: (781) 431-9100
Fax: N/A
Employees: 297
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $30.00
High Stock Price Target: $30.00
Low Stock Price Target: $30.00
Potential Upside/Downside: +78.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.18
Trailing P/E Ratio: 93.51
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $14.08 million
Net Margins: 5.11%
Pretax Margin: -6.16%
Return on Equity: -6.12%
Return on Assets: -5.20%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.34
Quick Ratio: 3.85

Sales & Book Value

Annual Sales: $270.26 million
Price / Sales: 4.40
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.23 per share
Price / Book: 2.70

Miscellaneous

Outstanding Shares: 70,610,000
Free Float: 32,320,000
Market Cap: $1.19 billion
Optionable: Optionable
Beta: 0.27

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. Sanj K. Patel (Age 55)
CEO & Chairman of the Board
Comp: $1.44M
Mr. Eben Tessari (Age 42)
Senior VP & COO
Comp: $643.75k
Dr. John F. Paolini (Age 59)
Senior VP & Chief Medical Officer
Comp: $753.7k
Mr. Mark Ragosa C.F.A. (Age 50)
Senior VP & CFO
Mr. Michael R. Megna CPA (Age 53)
Chief Accounting Officer & Group VP of Finance
Ms. Mei Jang
Senior VP of Technical Operations
Rachel Frank
Associate Director of Investor Relations
Mr. Chad Morin
Senior VP & Chief Compliance Officer
Ms. Madelyn Demsky Zeylikman (Age 50)
SVP, General Counsel & Secretary
Ms. Melissa Manno
Senior VP & Chief Human Resources Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KNSA Stock Analysis - Frequently Asked Questions

Should I buy or sell Kiniksa Pharmaceuticals stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" KNSA shares.
View KNSA analyst ratings or view top-rated stocks.
What is Kiniksa Pharmaceuticals' stock price target for 2024?: 1 Wall Street research analysts have issued 12-month price targets for Kiniksa Pharmaceuticals' shares. Their KNSA share price targets range from $30.00 to $30.00. On average, they predict the company's share price to reach $30.00 in the next twelve months. This suggests a possible upside of 77.4% from the stock's current price.
View analysts price targets for KNSA or view top-rated stocks among Wall Street analysts.
How have KNSA shares performed in 2024?: Kiniksa Pharmaceuticals' stock was trading at $17.54 at the beginning of the year. Since then, KNSA shares have decreased by 3.6% and is now trading at $16.91.
View the best growth stocks for 2024 here.
Are investors shorting Kiniksa Pharmaceuticals?: Kiniksa Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,210,000 shares, an increase of 11.8% from the March 15th total of 2,870,000 shares. Based on an average trading volume of 375,600 shares, the short-interest ratio is currently 8.5 days.
View Kiniksa Pharmaceuticals' Short Interest.
When is Kiniksa Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 23rd 2024.
View our KNSA earnings forecast.
How can I listen to Kiniksa Pharmaceuticals' earnings call?: Kiniksa Pharmaceuticals will be holding an earnings conference call on Tuesday, April 23rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Kiniksa Pharmaceuticals' earnings last quarter?: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) released its quarterly earnings results on Wednesday, February, 28th. The company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.15. The company had revenue of $83.40 million for the quarter, compared to analyst estimates of $72.31 million. Kiniksa Pharmaceuticals had a net margin of 5.11% and a negative trailing twelve-month return on equity of 6.12%.

What ETF holds Kiniksa Pharmaceuticals' stock?: Virtus LifeSci Biotech Products ETF holds 22,347 shares of KNSA stock, representing 2.12% of its portfolio.
What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO?: 1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Kiniksa Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD).
When did Kiniksa Pharmaceuticals IPO?: Kiniksa Pharmaceuticals (KNSA) raised $126 million in an IPO on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are Kiniksa Pharmaceuticals' major shareholders?: Kiniksa Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.20%), Hennion & Walsh Asset Management Inc. (0.18%) and Allspring Global Investments Holdings LLC (0.09%). Insiders that own company stock include Barry D Quart, John F Paolini, Mark Ragosa, Michael R Megna and Sanj K Patel.
View institutional ownership trends.
How do I buy shares of Kiniksa Pharmaceuticals?: Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KNSA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial